Analysis Of Efficacy And Prognostic Factors In Patients With Anlotinib At Advanced Non-small-cell Lung Cancer

Objective:The aim of this study is though a Retrospective analysis of the clinical treatment data of patients and side effects with advanced Non-small-cell lung cancer who treated by anlotinib in our hospital,and investigate the related prognostic factors affecting the curative effect.Methods:Collecting the clinical treatment data and general situation of advanced Non-small-cell lung cancer patients who has received anlotinib at oncology department of the first affiliated hospital of Nanchang University from June 2018 to September 2018.Statistical analysis was performed by using SPSS 22.0 software package,the Kaplan-Meier method was used to calculate survival rates,Log-rank test was used for univariate prognostic analysis.Cox regression model was used for multivariate prognostic analysis,to find the independent prognostic factor,Statistical results α=0.05(bilateral)was considered statistically different.Results:General situation: There are 104 patients with advanced non-small cell lung cancer were enrolled.The Complete response was 1 cases(0.9%),partial response was 12 cases(11.5%),stable disease was 47 cases(45.2%),progressive disease was44 cases(42.3%),objective remission rate was 12.5%,disease control rate was 57.7%.The median progression-free survival was 3.6 months.The rate of grade 2 adverse reactions was 26.9%,grade 3 adverse reactions was 8.7%,and there was no grade 4adverse reactions.Univariate analysis: High PS score,adenocarcinoma,N3 stage,M1 c stage,IVb stage and previous platinum-containing regimen chemotherapy were the poor prognostic factors of advanced NSCLC treated with Anlotinib(P<0.05).Multi-factors analysis: High PS score(HR=2.282,95%CI : 1.184-4.392,P=0.014)and N3 stage(HR=5.986,95%CI:1.864-19.219,P=0.004)were independent predictors of the efficacy of Anlotinib in the treatment of advanced NSCLC.Conclusion:The single drug of Anlotinib has definite efficacy and mild adverse reactions in the treatment of advanced NSCLC.High PS score,adenocarcinoma,N3 stage,M1 c stage,IVb stage and previous platinum-containing regimen chemotherapy were the poor prognostic factors of advanced NSCLC treated with Anlotinib(P<0.05).High PS score and N3 stage were the independent risk prognostic factors of in advanced Non-small-cell lung cancer(P<0.05).